Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C. Mirabella M, et al. Among authors: gasperini c. CNS Drugs. 2018 Oct;32(10):963-970. doi: 10.1007/s40263-018-0543-3. CNS Drugs. 2018. PMID: 30022464
Proteolytic balance in patients with multiple sclerosis during interferon treatment.
Giannelli G, De Marzo A, Scagnolari C, Bergamini C, Fransvea E, Bagnato F, Bellomi F, Millefiorini E, Gasperini C, Antonaci S, Antonelli G. Giannelli G, et al. Among authors: gasperini c. J Interferon Cytokine Res. 2002 Jun;22(6):689-92. doi: 10.1089/10799900260100187. J Interferon Cytokine Res. 2002. PMID: 12162880
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E; CoSa Study Group. Lugaresi A, et al. Among authors: gasperini c. Clin Neuropharmacol. 2008 May-Jun;31(3):167-72. doi: 10.1097/wnf.0b013e3181571a8e. Clin Neuropharmacol. 2008. PMID: 18520983
Emerging oral drugs for multiple sclerosis.
Gasperini C, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C. Gasperini C, et al. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. doi: 10.1517/14728214.13.3.465. Expert Opin Emerg Drugs. 2008. PMID: 18764723 Review.
The prevalence of multiple sclerosis in central Italy.
Millefiorini E, Cortese A, Di Rezze S, Barletta G, Bellantonio P, Batocchi AP, Di Battista G, Fiore S, Gasperini C, Grasso MG, Koudriatseva T, Totaro R, Durastanti V. Millefiorini E, et al. Among authors: gasperini c. Mult Scler. 2010 Dec;16(12):1432-6. doi: 10.1177/1352458510373263. Epub 2010 Sep 10. Mult Scler. 2010. PMID: 20834041
353 results